N onalcoholic fatty liver disease (NAFLD), a precursor to other liver diseases, is characterized by excessive hepatic triglyceride (TG) accumulation. NAFLD encompasses a spectrum of diseases ranging from simple fatty liver disease (steatosis) to nonalcoholic steatohepatitis (NASH). NASH is linked to obesity, type 2 diabetes, and cardiovascular disease (1) (2) (3) , and patients with NASH can develop cirrhosis and hepatocellular carcinoma (HCC) (4) (5) (6) . Although the mechanism(s) of NAFLD pathogenesis remains largely unclear, increased hepatic TG biosynthesis and deposition are known factors driving NAFLD. Consequently, we hypothesized that inhibiting TG synthesis in the liver could attenuate NAFLD.
Adenosine monophosphate (AMP)-activated protein kinase (AMPK) is a key enzyme involved in eukaryotic cellular energy balance, and it plays an important role in regulating glucose and lipid metabolism. AMPK consists of a, b, and g subunits; the a subunit can be activated by the cellular AMP/adenosine triphosphate (ATP) ratio (7) . The available evidence increasingly demonstrates that phosphorylation of hepatic AMPK counteracts hepatic steatosis by phosphorylating acetyl-coenzyme A carboxylase 1 (ACC1) or, alternatively, by increasing fatty acid (FA) oxidation and mitochondrial function (8) . AMPK activation also suppresses sterol regulatory elementbinding protein (SREBP)-1c expression, a key transcription factor that regulates FA and TG synthesis in the liver by inhibiting liver X receptor activity (9) . In addition, AMPK may protect against hepatic steatosis, hyperlipidemia, and accelerated atherosclerosis in insulin-resistant low-density lipoprotein receptor-deficient mice partly through suppressing SREBP-1c and SREBP-2-dependent lipogenesis (8) . SREBP-2 mainly increases cholesterol synthesis, whereas SREBP-1c enhances transcription of lipogenic genes including fatty acid synthetase (FAS) (10) to promote FA and TG biosynthesis. When considered together, these regulatory relationships point to AMPK as a potential target for treatment of NAFLD.
MicroRNAs (miRNAs) are a class of small (;21 to 23 nucleotides), endogenous, nonprotein-coding, highly conserved, and single-stranded gene products that posttranscriptionally regulate target genes' expression by binding to complementary regions in the 3 0 untranslated regions (3 0 -UTRs) of target messenger RNAs (mRNAs) (11, 12) . Recently, miRNAs have been identified as crucial regulators of lipid metabolism and metabolic diseases (13) . Several studies have reported that miR-122, miR-291-3p, miR-33, miR-30c, miR-24, miR-130, and miR-34a play essential roles in hepatic TG homeostasis (14) (15) (16) (17) (18) (19) (20) , and that miR-291-3p and miR-34a increase hepatic TG accumulation by targeting AMPK (16, 20) . The dysregulation of miR-1224-5p has been reported in human cancers, including lung cancer, colorectal cancer, malignant gliomas, and rectal cancer (21) (22) (23) (24) . miR-1224-5p also is upregulated in the liver of mice fed a high-fat diet (HFD) (25) ; however, the underlying mechanisms remain unknown. In this study, we found that miR-1224-5p promotes hepatic lipid metabolism by directly targeting the 3 0 -UTR of AMPKa1. Therefore, we suggest that miR-1224-5p/AMPKa1 signaling may be a pathological mechanism for NAFLD that warrants further investigation.
Methods and Materials

Animal experimentation
Male C57BL/6 mice aged 6 to 8 weeks and obese (ob/ob) mice aged 10 to 12 weeks were purchased from Model Animal Research Center of Nanjing University. All animal experiments were approved by the Animal Care and Protection Committee of Nanjing University-Nanjing Gulou Hospital (approval no. SYXK 2004-0013). The authors confirmed that all animals received human care and all animal experiments were performed in accordance with the relevant guidelines and regulations.
All mice were housed at 20°C to 24°C with humidity at 55% 6 10% and a 12-hour light/12-hour dark cycle; they had free access to food and water. Ob/ob mice (n = 5) and wild-type mice (n = 5) were fed a chow diet. Then, C57BL/6 mice were fed a standard chow diet or an HFD (FBSH, Shanghai, China) for 10 successive weeks.
In the course of injection, the mouse was restrained and the recombinant adenoviruses at a dose of 2 3 10 10 plaqueforming units in 150 mL of phosphate-buffered saline (PBS) per mouse were injected into the mouse tail vein by microinjector. HFD-fed mice were injected likewise with recombinant adenoviruses expressing miR-1224-5p inhibitor (Ad-1224 inhibitor) or with a negative control [adenovirus vector (Advector)] in the liver. C57 BL/6 mice fed a chow diet (n = 8) were injected with the recombinant adenoviruses expressing an miR-1224-5p mimic (Ad-1224 mimics) or with Ad-vector through the tail vein. Ten days after injection, livers of mice were harvested, snap frozen in liquid nitrogen, and then stored at 280°C for further analysis. In addition, mice fed an HFD for 10 weeks were then given metformin intragastrically at 200 mg/kg/d (26) , atorvastatin at 0.1 mg/kg/d (27) , and vitamin E at 100 mg/kg/d (28) (all Medchemexpress, Monmouth Junction, NJ), or placebo for 2 months. The metformin, atorvastatin, and vitamin E were prepared with gelatin (Sangon, Shanghai, China).
Adenovirus preparation
Ad-1224 mimics and Ad-1224 inhibitor were generated according to the manufacturer's instructions for the pAd-Easy system (Invitrogen, Carlsbad, CA). Ad-vector was used as a negative control. The following sequence of Ad-1224 mimics was inserted into pAd-Easy system: 5 0 -GUG AGG ACU GGG GAG GUG GAG GGU AGC AUC AUU AGA GCC AGA GCU CUG UCU CAG CUC CCU CUC CCC CCA CCU CUU CUC UCC UCA G-3 0 . The following sequence of Ad-1224 inhibitor was cloned into pAd-Easy system: 5 0 -GTG AGG ACT CCG GAG GTG GAG GTG AGG ACT CCG GAG GTG GAG GTG AGG ACT CCG GAG GTG GAG GTG AGG ACT CCG GAG GTG GAG GTG AGG ACT CCG GAG GTG GAG GTG AGG ACT CCG GAG GTG GAG GTG AGG ACT CCG GAG GTG GAG GTG AGG ACT CCG GAG GTG GAG-3 0 . To ensure that the aforementioned adenoviruses can exclusively express miRNA or its inhibitors in liver, we constructed a mouse albumin promoter in the sequence of the adenovirus vector. These viruses were diluted in PBS and injected in the mouse tail vein at a dose of 2 3 10 10 plaque-forming units per mouse. study, and the oleic acid (OA) and palmitic acid (PA; SigmaAldrich, St. Louis, MO) solutions were prepared according to described methods (29) . HepG2 cells and primary hepatocytes were treated with FA, a mixture of OA and PA at an equal molar ratio, for 24 hours to induce in vitro lipogenesis.
Cell transfections
The negative control and AMPKa1 small interfering RNA (siRNA) were obtained from GenePharma (Shanghai, China). RNAs were transfected into cells by lipofectamine 2000 reagent (Thermo Fisher Scientific, Waltham, MA) following the manufacturer's instructions. The transfection efficiency was evaluated by real-time polymerase chain reaction (PCR). After 48-hour transfection, the cells were harvested for total RNA or protein analysis.
RNA isolation and real-time PCR
Total RNA of tissues or cells were extracted using standard TRIzol reagent (Invitrogen, Shanghai, China). For miRNA analysis, total RNA was reverse transcribed using miScript II RT kit (Qiagen, Shanghai, China). Subsequently, real-time PCR was performed using a SYBR Green Premix Ex Taq (Takara, Japan) on the CFX96 system (Bio-Rad, Hercules, CA). In our study, U6 small nucleolar RNA and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) were used as internal controls in in vivo and in vitro experiments, respectively. The nucleotide primers used for reverse transcription were: 5 0 -GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC GCA CTG GAT ACG ACC TCC ACC-3 0 for miR-1224-5p; and 5 0 -GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC GCA CTG GAT ACG ACA AAT ATG-3 0 for U6. PCR primers for mouse miR-1224-5p were: forward, 5 0 -TCC GAA GTG AGG ACT GGG GA-3 0 ; and for U6 small nucleolar RNA: forward, 5 0 -GCG CGT GAA GCG TTC-3 0 . We used universal reverse primer, 5 0 -GTG CAG GGT CCG AGG T-3 0 ; GAPDH: forward, 5 0 -GGA GAG TGT TTC CTC GTC CC-3 0 , and reverse, 5 0 -ACT GTG CCG TTG AAT TTG CC-3 0 . Analysis of the data were performed by the comparative threshold-cycle method.
Biochemical analysis of aspartate transaminase and alanine transaminase
Serum aspartate transaminase and alanine transaminase levels were detected by using the aspartate aminotransferase assay kit and alanine aminotransferase assay kit (Nanjing Jiancheng Bioengineering Institute, Nanjing, China) with a biochem-immunoautoanalyzer (Beckman Coulter Inc., Brea, CA).
TG measurement
The TG content of liver tissue and cells was measured using a TG assay kit (Nanjing Jiancheng Bioengineering Institute) according to the manufacturer's instructions.
Western blot analysis
Hepatic tissues and cells were lysed using radioimmunoprecipitation assay lysis buffer (Beyotime Institute of Biotechnology, Shanghai, China) containing 50 mM Tris-HCl (pH 8.0), 150 mM NaCl, 5 mM MgCl 2 , 2 mM EDTA, 1 mM NaF, 1% NP40, and 0.1% sodium dodecyl sulfate, added with protease and phosphatase inhibitors (Roche, Shanghai, China). 50 mg proteins were separated by 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis, transferred to polyvinylidene difluoride membranes (Millipore, Burlington, MA), blocked with 5% nonfat dry milk (Sangon), and then incubated with a primary antibody at 4°C overnight. The blot was incubated with horseradish peroxidase-conjugated antiimmunoglobulin G (Bioworld Technology, St. Louis Park, MN), followed by detection with enhanced chemiluminescence (Cell Signaling Technology, Danvers, MA). Western blots were carried out using primary antibodies against AMPKa1 (1:2000; catalog no. ab32047; Abcam, Shanghai, China), ACC1 (1:2000; catalog no. ab45174; Abcam), phosphorylated ACC1 (1:1000; catalog no. ab68191; Abcam) and FAS (1:1000; catalog no. ab128870; Abcam), AMPK (1:1000; catalog no. 5831; Cell Signaling Technology) and phosphorylated AMPK (Thr172) (1:1000; catalog no. 2531; Cell Signaling Technology), SREBP-1 (1:1000; catalog no. bs70008; Bioworld Technology) and GAPDH (1:5000; catalog no. AP0063; Bioworld Technology).
Histological analysis of tissues and Nile red staining
For hematoxylin and eosin (H&E) staining, liver tissues were fixed in 4% paraformaldehyde in PBS and embedded in paraffin. The sections were subjected to standard H&E staining. In a brief, the slides were first incubated with H&E stain, then dehydrated with an alcohol gradient; the vacuoles were considered the lipid droplets. Next, for Oil red O staining, cryosections of liver were stained with 0.15% Oil red O (Sigma-Aldrich, Shanghai, China) according to standard procedures (30) . Briefly, the cryosections were warmed at room temperature for 30 minutes, and the sections were pretreated with isopropanol for 2 minutes. Then, the samples were stained with the prepared Oil red O for 30 minutes. After washing with 60% isopropanol for 1 minute for three times, the stained sections were mounted with glycogelatin. Micrographs were taken (CK Microscope; Olympus, Tokyo, Japan). For Nile red staining, 1 mM Nile red solution (Sigma-Aldrich) in Hanks balanced salt solution was added to samples. After incubating for 30 minutes at room temperature in the dark, Nile red solution was removed, the sections were washed thrice with Hanks balanced salt solution, and micrographs were taken (535 to 580 nm). The number and size of lipid droplets were measured by the Image J software (National Institutes of Health, Bethesda, MD).
Luciferase reporter assay
The predicted 3 0 UTR sequence of AMPKa1, binding to miR-1224-5p, was cloned from the genomic DNA of AML12 cells. Then, the sequence was inserted into the XbaI and SacI sites of the pmir-GLO control luciferase reporter vector (Promega, Fitchburg, WI). Similarly, the reporter plasmid containing mismatch mutation sites was constructed. The AML12 cells, incubated with adenoviruses for 24 hours, were cotransfected with the internal control vector pmir-GLO (Promega) and pmir-GLO-AMPKa1 3 0 UTR using lipofectamine 2000 reagent (Thermo Fisher Scientific) for 48 hours. Luciferase reporter assays were carried out using the Dual-Glo luciferase assay system (Promega, Fitchburg, WI).
Statistics
All data were expressed as mean 6 standard error of mean. Statistical differences were determined by the two-tailed unpaired Student t tests.
Results miR-1224-5p expression was increased in the liver of ob/ob mice and HFD-fed mice
As important regulators for lipid metabolism, many miRNAs were either upregulated or downregulated in the liver of HED-fed mice after microarray analysis (data accessible in the National Center for Biotechnology Information Gene Expression Omnibus database, accession number: GSE65978; https://www.ncbi.nlm.nih.gov/geo/) (25) . Elucidation of the concrete role of those miRNAs is crucial for understanding the pathology of NAFLD. Among those miRNAs, we observed significantly higher miR-1224-5p expression in HFD-fed mice than in mice fed a normal-fat diet (Fig. 1A) . To verify this finding, we used ob/ob mice and HFD-fed mice. First, we found that ob/ob and HFD-fed mice had increased hepatic lipid accumulation (Fig. 1B) and increased hepatic TG content (Fig. 1C) . Compared with their respective controls, HFD-fed mice (Fig. 1D ) and ob/ob mice (Fig. 1E ) had elevated hepatic levels of lipogenic proteins, such as SREBP-1 and FAS. Most notably, hepatic miR-1224-5p was upregulated not only in HFD-fed mice but also in ob/ob mice (Fig. 1F) . We conducted a correlation analysis to verify the association between miR-1224-5p expression and FAS or SREBP-1 levels. Our results showed that HFD-fed and ob/ob mice with high miR-1224-5p expression had significantly higher FAS and SREBP-1 expression than did the control mice ( Fig. 1G and Fig. 1H ).
In addition to the in vivo results, we found that that FA-stimulated primary hepatocytes had more and larger lipid droplets (Fig. 1I) , a higher lipid content (Fig. 1J) , and higher miR-1224-5p expression than did nonstimulated cells (Fig. 1L) . miR-1224-5p upregulation was accompanied by increased expression of SREBP-1 and FAS ( Fig. 1K and 1 M) . Together, the in vitro data support our finding that hepatic miR-1224-5p expression was significantly elevated in ob/ob mice and HFD-fed mice.
Inhibition of hepatic miR-1224-5p expression attenuated hepatic lipid accumulation in HFD-fed mice
To determine whether miR-1224-5p was associated with hepatic lipid accumulation, we challenged HFD-fed mice with Ad-1224 inhibitor or Ad-1224 mimics ( Fig. 2A) . Because the Ad-1224 inhibitor is cloned downstream of an albumin promoter ( Fig. 2A) , as expected, adenoviral overexpression of Ad-1224 inhibitor led to a significant reduction in hepatic miR-1224-5p expression (Fig. 2B) . Interestingly, the Ad-1224 inhibitor-challenged HFD-fed mice did not show changes in overall body weight (Fig. 2C) . However, they did have reduced liver weight as well as a reduced ratio of liver weight to body weight ( Fig. 2D and 2E) .
Next, to understand the reason for the reduced liver weight in the Ad-1224 inhibitor-challenged HFD-fed mice, we performed H&E and Oil red O staining, and found that the HFD-induced hepatic lipid droplets were greatly reduced in mice challenged with the Ad-1224 inhibitor (Fig. 2F) . Meanwhile, Ad-1224 inhibitor overexpression also decreased the hepatic lipid droplets and hepatic TG content (Fig. 2G) , and downregulated the hepatic protein levels of SREBP-1 and FAS (Fig. 2H) . This inhibition of miR-1224-5p was accompanied by significantly downregulated expression of SREBP-1 and FAS (Fig. 2I) .
Hepatic overexpression of miR-1224-5p promoted hepatic lipid accumulation
To examine whether miR-1224-5p directly causes hepatic steatosis, chow-fed C57BL/6 mice were challenged with Ad-1224 mimics via tail-vein injection. At 10 days postinjection, hepatic miR-1224-5p expression levels had increased about 90%, suggesting that miR-1224-5p was successfully overexpressed in the livers of chow-fed C57BL/6 mice (Fig. 3A) . Similar to the results of the Ad-1224 inhibitor, Ad-1224 mimics did not change the body weight of mice (Fig. 3B) , but did increase the liver weight and ratio of liver weight to body weight when compared with the vector-only control group (Fig. 3C  and 3D ). Furthermore, H&E and Oil red O staining analyses confirmed that Ad-1224 mimics promoted hepatic lipid accumulation and increased the number of lipid droplets (Fig. 3E and 3F ). Ad-1224 mimics consistently induced a significant increase of hepatic TG (Fig. 3G) , which was associated with increased levels of hepatic SREBP-1 and FAS in chow-fed C57BL/6 mice (Fig. 3H) .
Suppression of miR-1224-5p expression attenuated FA-induced in vitro lipid accumulation
To further verify our in vivo findings, we treated mouse primary hepatocytes with a FA mixture consisting of OA and PA for 24 hours. The adenoviral overexpression of Ad-1224 in primary hepatocytes led to a reduction of endogenous miR-1224-5p (Fig. 4A) , accompanied by reduced lipid accumulation (Fig. 4C) . Meanwhile, the knockdown of miR-1224-5p significantly decreased the lipid droplet number and size (Fig. 4E) , as well as the cellular TG content in the presence of FA (Fig. 4G) . Similar results were also obtained in HepG2 cells (Supplemental Fig. 1A-1D) .
To determine whether miR-1224-5p can cause increased TG deposition, we overexpressed Ad-1224 mimics in primary hepatocytes (Fig. 4B) . Nile red staining analysis of the primary hepatocytes showed increased lipid droplet accumulation ( Fig. 4D and 4F ) and increased cellular TG content (Fig. 4G ). In addition, FA-induced upregulation of SREBP-1 and FAS protein expression decreased after Ad-1224 inhibitor treatment ( Fig. 4H and  4I ) and increased after Ad-1224 mimic treatment ( Fig. 4J  and 4K ). All these changes were closely associated with expression of SREBP-1 and FAS. Thus, suppression of 
miR-1224-5p mediated lipid accumulation by directly targeting AMPKa1
Our bioinformatics analysis indicated that that miR-1224-5p should be capable of binding the 3 0 -UTR of AMPKa1 mRNA (Fig. 5A) , suggesting that AMPKa1, an important catalytic subunit of AMPK, is a potential miR-1224-5p target gene. To confirm that prediction, we generated a Renilla luciferase reporter plasmid containing the 3 0 -UTR of mouse AMPKa1 with miR-1224-5p binding sites. Our reporter assay results showed that miR-1224-5p overexpression significantly reduced luciferase activity in primary hepatocytes transfected with the luciferase reporter plasmid but not the reporter plasmid containing mismatch mutation sites (Fig. 5B) . In addition, miR-1224-5p overexpression in primary hepatocytes resulted in reduced AMPK phosphorylation and total AMPKa1 protein. Furthermore, the level of phosphorylated ACC1 (p-ACC1), a known target of p-AMPK, was substantially decreased in primary hepatocytes transfected with the Ad-1224 mimics (Fig. 5C  and 5D ). Similarly, Ad-1224 mimics reduced expression of peroxisome proliferator-activated receptor a (PPARa) and silent mating-type information regulation 2 homolog-1 (Sirt1) in primary hepatocytes, indicating that PPARa and Sirt1 are also potential targets of miR-1224-5p (Supplemental Fig. 1E ). In agreement with these results, p-ACC1 levels were elevated in primary hepatocytes transfected with Ad-1224 inhibitor ( Fig. 5E and 5F ), and PPARa and Sirt1 were upregulated in Ad-1224 inhibitor-transfected HepG2 cells (Supplemental Fig. 1D) .
To verify the in vitro results in vivo, we overexpressed Ad-1224 mimics in the livers of C57BL/6 mice through our standard tail-vein injection protocol, and subsequently observed substantially downregulated levels of hepatic AMPKa1 and p-AMPK (Fig. 5G and 5H ). As expected, administration of Ad-1224 inhibitor to HFD-fed mice yielded the opposite result ( Fig. 5I and 5J ). These findings established that AMPKa1 is a direct target of miR-1224-5p. Additionally, we found that Ad-1224 mimics reduced expression of hepatic PPARa and Sirt1 in chow-fed C57BL/6 mice, further suggesting that PPARa and Sirt1 are also miR-1224-5p targets (Supplemental Fig. 1F) .
Finally, we suppressed AMPKa1 via siRNA silencing to investigate whether AMPKa1 mediates miR-1224-5p-induced lipid accumulation. First, we found that AMPKa1 and p-AMPK levels, indeed, were suppressed in primary hepatocytes transfected with AMPKa1 siRNA (Fig. 5K) . Moreover, AMPKa1 silencing reduced the expression of p-AMPK and p-ACC1 (Fig. 5L and 5M) , and reversed Ad-1224 inhibitor-induced decreases of cellular TG content (Fig. 5N) . In addition, knockdown of AMPKa1 overcame the effects of Ad-1224 inhibitor on lipid accumulation in AML12 and HepG2 cells (Supplemental Fig. 2A-2F) . Therefore, miR-1224-5p may enhance lipid accumulation by inhibiting AMPKa1 expression and activity.
Interestingly, we found that high glucose treatment also increased the expression of miR-1224-5p; on the contrary, insulin decreased the expression of miR-1224-5p (Supplemental Fig. 4A) . Furthermore, knockdown of miR-1224-5p attenuated glucose and insulin tolerance in HFD-fed mice, but miR-1224-5p overexpression triggered glucose and insulin tolerance in mice fed a normalfat diet (Supplemental Fig. 4B-4F ).
miR-1224-5p downregulation was associated with metformin-reversed hepatic lipid accumulation in HFD-fed mice
Metformin is a known AMPK activator. In this study, metformin reduced lipid accumulation in HFD-fed mice ( Fig. 6A and 6B ). To examine whether miR-1224-5p influences the effects of metformin treatment, we analyzed hepatic miR-1224-5p levels in HFD-fed mice treated with metformin for 10 weeks. Metformin significantly downregulated miR-1224-5p expression (Fig. 6C) . In addition, data indicated that atorvastatin treatment and vitamin E treatment reduced hepatic TG content and miR-1224-5p expression in HFD-fed mice (Supplemental Fig. 2B -2 F and Supplemental Fig. 3A) . To be more specific, we found that MK3903, a selective AMPK activator, significantly inhibited miR-1224-5p expression (Supplemental Fig. 4A ). Finally, metformin treatment of HFD-fed mice consistently increased hepatic AMPKa1, AMPK, and p-AMPK levels, and suppressed hepatic SREBP1, FAS, and p-ACC1 levels ( Fig. 6D and 6E) . Together, these data support a role for miR-1224-5p/AMPK in mediating the effects of common anti-NAFLD drugs.
Discussion
In this study, we identified miR-1224-5p as a mediator of hepatic lipid accumulation. Ad-1224 inhibitors significantly attenuated lipogenesis and lipid droplet accumulation in HFD-fed mice, FA-stimulated primary hepatocytes, and HepG2 cells. Likewise, Ad-1224 mimics promoted hepatic lipid accumulation in chowfed C57BL/6 wild-type mice. Furthermore, we identified AMPKa1 as a direct target of miR-1224-5p. miR-1224-5p binds the 3 0 -UTR of AMPKa1, thereby suppressing expression of AMPKa1 and its downstream signaling targets. We also showed that metformin treatment in HFD-fed mice downregulated hepatic miR-1224-5p expression. miR-1224-5p expression can also be inhibited by other anti-NAFLD drugs, including atorvastatin and vitamin E (31, 32) . In addition to AMPK, we identified PPARa and Sirt1 as potential targets of miR-1224-5. Taken together, our findings suggest that Ad-1224 inhibitors could be used to prevent NAFLD. miRNAs are small (about 22 nucleotides), highly conserved endogenous RNAs that regulate gene expression through incomplete base pairing. miRNAs have been reported to play important roles in the pathology of various diseases, including NAFLD (33) . For example, miR-122 may serve as an indicator of NAFLD severity and may provide additional insight to the diagnosis and staging of NAFLD in clinical practice (19) . miR-33a/b contributes to lipid and cholesterol metabolism by inhibiting expression of SREBPs, and miR-33a/b contributes to liver dysfunction via lipotoxicity and oxidation stress (34) . miR-34a is significantly increased in ob/ob mice and patients with NAFLD, and miR-34a takes part in both the steatosis and apoptosis of hepatocytes, suggesting that miR-34a is associated with NAFLD progression (35) (36) (37) . Moreover, miR-21, miR-29, and miR-125b participate in the progression and extent of hepatic steatosis-related liver injury (38) . Thus, miRNAs may serve as potential biomarkers for NAFLD that would help clinicians rapidly diagnose and formulate treatment strategies.
Previous studies indicated that miR-1224-5p was aberrantly expressed and possibly considered as a biomarker in some human cancers, including gliomas, lymphoma, lung cancer, and rectal cancer (21) (22) (23) (24) . miR-1224 is upregulated in the liver of mice given carbon tetrachloride and acetaminophen, and in patients who died of acute liver failure (39) . Carbon tetrachloride is a commonly used chemical to establish an animal model of HCC, raising a possibility that miR-1224 might also be involved in the development of HCC. Although much remains unknown regarding the roles of miR-1224-5p and its targets in cancers, miR-1224-5p is known to act as a tumor suppressor in malignant gliomas by targeting CREB1 (21), whose coactivator, CRTC2, suppresses hepatic lipid metabolism by disrupting SREBP-1 transport (40) , suggesting miR-1224-5p may be relevant to hepatic lipid metabolism. In the current study, miR-1224-5p was significantly elevated in the livers of ob/ob mice and HFD-fed mice, as well as in FA-treated primary hepatocytes. AMPKa1 was identified as an important target for miR-1224-5p. Therefore, we propose that miR-1224-5p should be further evaluated as a novel biomarker for NAFLD. As a central metabolic sensor, AMPK can directly repress transcriptional activity of SREBP family members, which are closely associated with synthesis of FA, TG, and cholesterol (8, (41) (42) (43) (44) . SREBP-1 (including the SREBP-1a and SREBP-1c isoforms) and SREBP-2 are the two members of the mammalian SREBP family. SREBP-1 is mainly involved in FA and TG biosynthesis. For example, it can enhance hepatic de novo lipogenesis by activating FAS expression (45) . SREBP-2, on the other hand, takes part in cholesterol biosynthesis by promoting 3-hydroxy-3-methylglutaryl-coenzyme A reductase expression (46) . Therefore, downregulation of AMPKa1 expression may allow SREBP family members to activate excessive lipid synthesis and accumulation in the liver. In this study, we established AMPKa1 as a direct target of miR-1224-5p. As a result, miR-1224-5p enhanced hepatic lipid deposition by inhibiting AMPKa1 expression along with activating the SREBP family. Meanwhile, AMPK phosphorylates and deactivates ACC, the rate-limiting enzyme for FA biosynthesis, resulting in suppressing FA synthesis (47) . Furthermore, AMPK directly stimulates free FA uptake into cells by translocating the FA translocase CD38 to the plasma membrane (48) . Taken together, suppression of AMPKa1 expression by miR-1224-5p may cause hepatic steatosis by enhancing de novo lipogenesis. In addition, PPARa and Sirt1 can increase the oxidation of FA and ameliorate hepatic insulin resistance and steatosis (49, 50) . PPARa and Sirt1 can be activated by AMPK (51, 52) . In this study, miR-1224-5p suppressed the expression of PPARa and Sirt1, raising the possibility that PPARa and Sirt1 are either direct targets of miR-1224-5p or are indirectly downregulated by AMPKa1. Additional experiments are needed to investigate those hypotheses. Lipid metabolism is closely associated with glucose metabolism (53) . Here, we found that knockdown of miR-1224-5p also ameliorated glucose tolerance and insulin tolerance, suggesting that miR-1224-5p is probably involved in both of these. Additional studies are needed to explore the precise molecular mechanisms of miR-1224-5p in glucose metabolism. To further investigate the importance of miR-1224-5p in regulating lipogenesis, we examined the effects of anti-NAFLD drugs on miR-1224-5p and AMPK expression in hepatocytes. Interestingly, we found that metformin, atorvastatin, and vitamin E all significantly suppressed miR-1224-5p expression and increased AMPK expression. According to previous studies, metformin, atorvastatin, and vitamin E have different anti-NAFLD mechanisms. Metformin shows its beneficial effects related to the phosphorylation and nuclear export of liver kinase B1, which activates AMPK to stimulate ATP-producing catabolic pathways (i.e., glycolysis, FA oxidation, and mitochondrial biogenesis) and to inhibit ATP-consuming anabolic processes (54) . Metformin is thought to inhibit hepatosteatosis by enhancing AMPK/mTORC1 axis-mediated autophagy and FA oxidation, and by restoring SIRT1-mediated autophagy induction via an AMPK-independent pathway (55, 56) . In addition, metformin may inhibit hepatosteatosis by reducing hepatic tumor necrosis factor-a expression and by suppressing ribosomal protein S6 kinase, which is a serine kinase downstream of the AMPKa1 protein that directly phosphorylates IRS-1 and inhibits insulin signaling (57, 58) . Metformin also suppresses hepatic tumor necrosis factor a mRNA expression and reverses several tumor necrosis factor-inducible responses that are likely to promote hepatic steatosis and necrosis (58) . Similarly, metformin inhibits hepatic inflammatory responses by blunting JNK1 and NF-kB signaling (59, 60) . Atorvastatin inhibits lipid synthesis by activating the CaMKK-b/AMPK axis that subsequently targets apolipoprotein B100, and vitamin E may inhibit hepatic lipid accumulation through Akt/ AMPK/mTOR pathway-mediated autophagy (61, 62) .
Thus, based on the available evidence, AMPK may be considered as the common target of metformin, atorvastatin, and vitamin E. In fact, we found in this study that a selective AMPK activator (MK3903) also decreased miR-1224-5p expression in AML12 cells. Consequently, the results of this study showed that metformin, atorvastatin, and vitamin E could reduce the hepatic expression of miR-1224-5p in HFD-fed mice, suggesting that miR-1224-5p may contribute to metformin-, atorvastatin-, or vitamin E-induced reduction of lipid droplet accumulation through activating AMPK. miR-1224-5p is perhaps a shared target of anti-NAFLD drugs.
In summary, we have shown that miR-1224-5p can enhance expression of lipogenic genes and hepatic TG accumulation by directly targeting AMPKa1. Therefore, Ad-1224 inhibitors may have therapeutic effects on fatty liver disease. Our findings also point to a role for reduced hepatic miR-1224-5p expression in mediating or enhancing the beneficial effects of metformin, atorvastatin, and vitamin E in NAFLD prevention and treatment.
